[1] 杨雷, 郑荣寿, 王宁, 等.  2013年中国甲状腺癌发病与死亡情况[J]. 中华肿瘤杂志, 2017, 39(11): 862-867.   doi: 10.3760/cma.j.issn.0253-3766.2017.11.010
Yang L, Zheng RS, Wang N, et al.  Analysis of Incidence and Mortality of Thyroid Cancer in China, 2013[J]. Chin J Oncol, 2017, 39(11): 862-867.   doi: 10.3760/cma.j.issn.0253-3766.2017.11.010
[2] 赵腾, 梁军, 李田军, 等.  分化型甲状腺癌131I治疗前刺激性Tg动态变化与远处转移的关系[J]. 中国医学科学院学报, 2015, 37(3): 315-319.   doi: 10.3881/j.issn.1000-503X.2015.03.013
Zhao T, Liang J, Li TJ, et al.  Relationship between Variation of Pre-ablation Stimulated Thyroglobulin and Distant Metastasis in Patients with Differentiated Thyroid Cancer[J]. Acta Acad Med Sin, 2015, 37(3): 315-319.   doi: 10.3881/j.issn.1000-503X.2015.03.013
[3] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[4]

Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2017.
[5] 韩婧, 康骅.  甲状腺癌的发病现状及影响因素[J]. 实用预防医学, 2018, 25(7): 894-897.   doi: 10.3969/j.issn.1006-3110.2018.07.037
Han J, Kang H.  Prevalence and influencing factors of thyroid cancer[J]. Pract Prev Med, 2018, 25(7): 894-897.   doi: 10.3969/j.issn.1006-3110.2018.07.037
[6] Lin JD, Hsueh C, Chao TC.  Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis[J]. Medicine, 2015, 94(26): e1063-.   doi: 10.1097/MD.0000000000001063
[7] 李田军, 林岩松, 梁军, 等.  131I治疗前刺激性Tg对乳头状甲状腺癌远处转移的预测价值[J]. 中华核医学与分子影像杂志, 2012, 32(3): 189-191.   doi: 10.3760/cma.j.issn.2095-2848.2012.03.007
Li TJ, Lin YS, Liang J, et al.  The value of pre-ablation stimulated thyroglobulin in predicting distant metastasis of papillary thyroid cancer[J]. Chin J Nucl Med Mol Imaging, 2012, 32(3): 189-191.   doi: 10.3760/cma.j.issn.2095-2848.2012.03.007
[8] 王宸, 赵腾, 李娇, 等.  分化型甲状腺癌肺转移131I治疗后早期Tg变化与远期临床转归的关系[J]. 中华核医学与分子影像杂志, 2017, 37(9): 555-558.   doi: 10.3760/cma.j.issn.2095-2848.2017.09.007
Wang C, Zhao T, Li J, et al.  Relationship between the initial change of Tg and outcome in differentiated thyroid carcinoma patients with pulmonary metastases after 131I treatment[J]. Chin J Nucl Med Mol Imaging, 2017, 37(9): 555-558.   doi: 10.3760/cma.j.issn.2095-2848.2017.09.007
[9] González C, Aulinas A, Colom C, et al.  Thyroglobulin as early prognostic marker to predict remission at 18−24 months in differentiated thyroid carcinoma[J]. Clin Endocrinol, 2014, 80(2): 301-306.   doi: 10.1111/cen.12282
[10] Piccardo A, Arecco F, Puntoni M, et al.  Focus on High-Risk DTC Patients: High Postoperative Serum Thyroglobulin Level Is a Strong Predictor of Disease Persistence and Is Associated to Progression-Free Survival and Overall Survival[J]. Clin Nucl Med, 2013, 38(1): 18-24.   doi: 10.1097/RLU.0b013e318266d4d8
[11] Toubeau M, Touzery C, Arveux P, et al.  Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer[J]. J Nucl Med, 2004, 45(6): 988-994.
[12] 林岩松, 李娇.  2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读: 分化型甲状腺癌131I治疗新进展[J]. 中国癌症杂志, 2016, 26(1): 1-12.   doi: 10.3969/j.issn.1007-3969.2016.01.001
Lin YS, Li J.  The interpretation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma: New progress in radioactive iodine therapy of differentiated thyroid carcinoma[J]. China Oncol, 2016, 26(1): 1-12.   doi: 10.3969/j.issn.1007-3969.2016.01.001
[13]

周琼, 陈森良, 罗淼, 等. 血清Tg和TgAb水平监测在分化型甲状腺癌患者131I清甲治疗中的临床意义[J/OL]. 中国医学前沿杂志: 电子版, 2017, 9(9): 105−108[2018−11−14]. http://mall.cnki.net/onlineview/MagaView.aspx?fn=yxqy201709*1*.DOI: 10.12037/YXQY.2017.09-25.

Zhou Q, Chen SL, Luo M, et al. Clinical significance of the levels of serum Tg and TgAb in the 131I ablation therapy for patients with differentiated thyroid cancer[J/OL]. Chin J Front Med Sci: Electron Version, 2017, 9(9): 105−108[2018−11−14]. http://mall.cnki.net/onlineview/MagaView.aspx?fn=yxqy201709*1*.DOI: 10.12037/YXQY.2017.09-25.
[14] Dufour DR.  Thyroglobulin Antibodies-Failing the Test[J]. J Clin Endocrinol Metab, 2011, 96(5): 1276-1278.   doi: 10.1210/jc.2011-0681
[15] 赵腾, 梁军, 林岩松.  131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J]. 国际放射医学核医学杂志, 2015, 39(1): 61-66.   doi: 10.3760/cma.j.issn.1673-4114.2015.01.013
Zhao T, Liang J, Lin YS.  The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J]. Int J Radiat Med Nucl Med, 2015, 39(1): 61-66.   doi: 10.3760/cma.j.issn.1673-4114.2015.01.013
[16] Do MY, Rhee Y, Kim DJ, et al.  Clinical Features of Bone Metastases Resulting from Thyroid Cancer: A Review of 28 Patients over a 20-year Period[J]. Endocr J, 2005, 52(6): 701-707.   doi: 10.1507/endocrj.52.701
[17] 林岩松, 张彬, 梁智勇, 等.  复发转移性分化型甲状腺癌诊治共识[J]. 中国癌症杂志, 2015, 25(7): 481-496.   doi: 10.3969/j.issn.1007-3969.2015.07.001
Lin YS, Zhang B, Liang ZY, et al.  Consensus on diagnosis and treatment of recurrent and metastasis differentiated thyroid carcinoma[J]. China Oncol, 2015, 25(7): 481-496.   doi: 10.3969/j.issn.1007-3969.2015.07.001
[18] Park EK, Chung JK, Lim IH, et al.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans[J]. Eur J Nucl Med Mol Imaging, 2009, 36(2): 172-179.   doi: 10.1007/s00259-008-0912-0
[19] 陈鹏, 宋长祥, 陆武, 等.  首次131I治疗前刺激性甲状腺球蛋白在预测颈部及远处转移性分化型甲状腺癌的意义[J]. 中国癌症杂志, 2017, 27(12): 953-958.   doi: 10.19401/j.cnki.1007-3639.2017.12.006
Chen P, Song CX, Lu W, et al.  The significance of stimulated thyroglobulin in predicting neck and distant metastasis in postoperative patients with differentiated thyroid carcinoma before the first 131I ablation therapy[J]. China Oncol, 2017, 27(12): 953-958.   doi: 10.19401/j.cnki.1007-3639.2017.12.006
[20] 张桂芝, 谭建, 刘雪辉, 等.  131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J]. 中华核医学杂志, 2010, 30(4): 259-263.   doi: 10.3760/cma.j.issn.0253-9780.2010.04.011
Zhang GZ, Tan J, Liu XH, et al.  Influential factors on the effectiveness of 131I treatment on post-surgical differentiated thyroid cancer patients[J]. Chin J Nucl Med, 2010, 30(4): 259-263.   doi: 10.3760/cma.j.issn.0253-9780.2010.04.011
[21] 李从心, 侯敏, 任超, 等.  中低危分化型甲状腺癌经131I治疗后短期Tg转阴情况的动态监测[J]. 中国医学科学院学报, 2016, 38(3): 351-355.   doi: 10.3881/j.issn.1000-503X.2016.03.020
Li CX, Hou M, Ren C, et al.  Serial Thyroglobulin Variation Trend Shortly after Radioiodine Therapy in Poorly to Moderately Differentiated Recurrent Thyroid Cancer[J]. Acta Acad Med Sin, 2016, 38(3): 351-355.   doi: 10.3881/j.issn.1000-503X.2016.03.020